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Aim: Dysphagia is a known complication in Pompe Disease (PD), a severe metabolic myopathy due to alpha-
glucosidase deficiency. Enzyme replacement therapy (ERT) with alglucosidase alfa is the only approved therapy for
PD. Presently no data are available on the effects of ERT on dysphagia in PD patients. The aim of this work is to
evaluate the course of this complication in a 6 years old boy affected by PD after treatment with ERT.
Methods: Dysphagia was assessed by Videofluoroscopic Swallowing Study (VFSS) at baseline, before the start of
ERT and after 36 months of therapy. We used the Dysphagia Severity Rating Scale (DSS) to define the severity grade
of dysphagia.
Results: VFSS performed at baseline revealed complete incoordination of oral stage swallowing which was
classified as a grade 1 dysphagia according to DSS. After 36 months of treatment VFSS revealed normal swallowing,
classified as grade 0 by DSS.
Conclusion: Our results suggest that ERT is effective in improving dysphagia. VFSS may be a useful tool to
investigate and monitor swallowing disorders in patients affected by PD.
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Pompe Disease (PD) (OMIM 232300, glycogen storage
disease type II, acid maltase deficiency) is a rare metabolic
myopathy, due to the deficiency of the lysosomal acid-
α-glucosidase (GAA) (E.C. 3.2.1.20) [1,2]. The overall
incidence of PD is estimated 1 in 40,000 live births [3,4].
The deficiency of GAA leads to generalized glycogen
accumulation, that is most relevant for the clinical mani-
festations in heart and skeletal muscles. The phenotype
of the disease encompasses a continuum that ranges
from severe, early-onset forms to attenuated, late-onset
phenotypes. The severe end of this spectrum is traditio-
nally referred to as the “classic infantile” form, which pre-
sents within the first months of life with severe and
progressive hypotonia, hypertrophic cardiomyopathy,* Correspondence: parenti@unina.it
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reproduction in any medium, provided the ormacroglossia, feeding difficulties, recurrent respiratory
infections, and failure to thrive. If untreated, classic
infantile patients generally die in the first year of life [5-7].
Non-classic infantile-onset forms share a similar clinical
picture, but with milder or absent heart involvement,
which may be limited to ECG abnormalities [8].
In the late-onset forms symptoms may present at any age
from childhood to late adulthood, cardiac involvement is
generally absent and the clinical manifestations are mostly
related to skeletal muscle involvement, with progressive
motor impairment, respiratory failure, and premature death.
Typical biochemical markers of PD are the elevated
levels of transaminases and creatine kinase (CK) in
blood, but these values vary considerably among different
patients, and show broad fluctuations in time [9].
The definitive diagnosis of PD relies on the demonstration
of reduced or absent GAA activity in lymphocytes, cultured
fibroblasts, or muscle biopsies [10], and on the identification
of mutations of the GAA gene.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Replacement Therapy (ERT) with recombinant human
alglucosidase alfa (Myozyme®, Genzyme Corporation,
Cambridge, MA, USA). This therapy is based on periodic
infusions of the recombinant enzyme, that is delivered to
tissues where it replaces the defective GAA. Several clinical
trials in classic infantile PD demonstrated remarkable
success of this approach in correcting cardiac pathology
and function and in extending patients’ survival, whereas
the response of skeletal muscle was less striking [11-13].
ERT seemed to be more effective when started earlier [14].
Long-term administration of ERT has modified
the natural course of PD, and different complications,
previously unrecognized, have become evident [15], inclu-
ding conductive and neurosensorial hearing impairment
[16], intracranial artery abnormalities [17], osteopenia and
osteoporosis [18]. Recently new strategies for the treatment
of PD are emerging [19].
Although feeding difficulties have been frequently
reported and are commonly considered as part of the typ-
ical PD phenotype, only recently particular attention has
been paid to the characterization of dysphagia and swal-
lowing disorders [20-22]. These complications may sub-
stantially impact on the quality of life of patients and may
lead to malnutrition, dehydration, weight loss and failure to
thrive. In addition, airway invasion and aspiration may
occur, increasing the risk of potentially lethal respiratory
infections. Ineffective cough, due to the involvement of
respiratory muscles, contributes to the risk of aspiration
pneumonias.
Due to the severe consequences of dysphagia, its iden-
tification is relevant for the appropriate management of
PD patients. Although at present there are no published
studies on the effects of ERT on dysphagia, accurate and
serial evaluations of swallowing may also be useful as
markers to assess the efficacy of therapy in PD.
Dysphagia can be investigated with Videofluoroscopy
Swallowing Study (VFSS) or with fibreoptic endoscopy.
VFSS may be preferable as it is less invasive and easily
tolerated, in infants and children. In addition, by VFSS it
is possible to examine the bolus progression, to characterize
the involvement of different stages of swallowing
(oral, pharyngeal and esophageal), and to detect aspiration
of contrast medium into the airways [23].
Here for the first time we present the data obtained in a
patient with infantile-onset PD that was studied by VFSS
before the start of ERT and after 36 months of therapy.
Case report
CF, a 6-year-old boy, is affected by the nonclassic infantile
form PD, and has received ERT with alglucosidase alfa
(Myozyme®) since the age of 2.3 years.
He was born from healthy, non-consanguineous parents.
Pregnancy was characterized by reduced fetal movements.Breast feeding difficulties and feeble cry were reported,
since the first days of life. At 2 years of age he was referred
to medical attention because of severe hypotonia, recurrent
respiratory tract infections, macroglossia, open drooping,
tent shaped mouth and failure to thrive. At that time he
was able to sit, but was unable to stand.
Chewing and swallowing problems were also reported,
that caused feeding difficulties and insufficient caloric intake.
Blood biochemistry showed increased serum levels of
aspartate aminotransferase (approximately 7-fold the upper
normal value), alanine aminotransferase (2.5-fold the upper
normal range) and creatine kinase (3.7-fold the upper
normal range). Electrocardiography showed short PR
interval (80 msec).
A diagnosis of PD was suspected when he was
2.3 years old, and confirmed by GAA enzymatic assay
in lymphocytes and fibroblasts. The molecular analysis
of the GAA gene showed the mutations [c.-32-13 T > G]
and [c.1856 G > A] on one allele and [c.1655 T > C] on
the other allele.
Due to the reported chewing and swallowing difficulties,
a VFSS was performed before the start of ERT, by ad-
ministering oral boluses of 5 ml liquid barium according
to standard (published) procedures [23]. VFSS showed
complete incoordination of the oral stage swallowing
with anterior positioning of bolus, weakness of labial
and oral cavity muscles and delayed bolus transit. Weak
and incoordinated tongue motion was ineffective for
swallowing with spilling of barium boluses from the
mouth. Epiglottis deflection was normal and pharyngeal
and esophageal stages of swallowing were regular. No
airway invasion was evident.
According to a dysphagia severity scale (DSS) (adapted
by Gates et al. [24]), dysphagia was limited to oral stage
and classified as grade 1 severity (Table 1). A supportive
speech therapy was started.
ERT with alglucosidase alfa was started at the age of
2.3 years at a dose of 20 mg/kg/14 days. The patient was
periodically monitored.
At the age of 6.3 years, after 36 months of ERT, no
progression of clinical manifestations related to muscle
involvement was observed and the general clinical picture
seemed stable. Physical examination still showed gene-
ralized hypotonia and weak tendon reflexes. The increase
of serum transaminases and creatine phosphokinase
persisted. Recurrent pneumonias were reported, but the
patient never required invasive ventilation. Facial-muscle
weakness with open drooping mouth, expressionless face,
absence of horizontal forehead lines, ptosis of the eyelid
persisted. Hearing loss, impaired speech with articulatory
disorders and hypernasal resonance were also evident.
The feeding difficulties were improved and no additional
problems in drinking or eating food of any consistence
were reported.
Table 1 Dysphagia Severity Rating Scale (adapted by Gates et al. [23])
0 Normal swallowing
1 Minimal dysphagia VFFS shows a slight deviation from a normal swallow; impairment limited to oral stage
2 Mild dysphagia swallowing suggestion Presence of oro-pharyngeal dysphagia; can be treated by means of specific swallowing suggestion
3 Mild to moderate dysphagia Presence of oro-pharyngeal dysphagia potential for aspiration exists but can be
diminished by specific swallowing techniques
4 Moderate dysphagia Presence of oro-pharyngeal dysphagia; potential for aspiration exists: trace aspiration
can be seen at VFSS
5 Severe dysphagia Presence of aspiration; nothing by mouth is recommended
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age of 6.3 years. Substantial improvement of swallowing
mechanisms was observed, that correlated with the
reported absence of feeding difficulties. Barium boluses
were regularly inserted without spillage. The oral stage
was regular and oral acceptance was coordinated. Tongue
thrusts were coordinated and effective to push the food.
Epiglottis deflection was regular. The transit of barium
contrast medium was normal pharyngeal and esophageal
phases. In summary, VFSS revealed the absence of dyspha-
gia, that classified as grade 0 by the DSS score (Table 1).
Discussion
This is the first case of a single PD infantile patient with a
documented improvement of dysphagia after three years of
ERT. The improvement of dysphagia was assessed by VFSS,
performed before the start of ERT and after 36 months of
treatment, and by a DSS scoring scale. Dysphagia has already
been reported in PD patients. A study of 13 untreated children
with classic infantile PD, showed that VFSS abnormalities
were detectable in all patients, including a 15-day-old infant
[20]. In this study the severity of dysphagia was rated on the
basis of clinical information, and of the need for special dietary
recommendations (normal foods, modified foods, or non-
oral nutrition). In this group of patients a second assess-
ment of VFSS was not performed after the start of ERT.
Van Gelder’s et al. [21] examined the course of dysphagia
in four patients on ERT, by fibreoptic endoscopy. By this
approach, dysphagia apparently remained stable during
treatment in three patients and worsened in one. ERT
seemed to reduce feeding difficulties in some patients, who
could discontinue nasogastric tube feeding, but there was
no complete normalization of swallowing, even in patients
who were orally fed. In this study no data before the start
of ERT were available.
In our patient, at diagnosis, VFSS showed a weak and
incoordinated swallowing during the oral phase, a finding
already reported in PD patients [20]. After 36 months of
therapy VFSS showed coordinated swallowing mechanisms,
with effective deglutition. The DSS improved from 1 to 0.
Although this was a subtle change, it may be clinicallyrelevant in a progressive disease like PD in which
symptoms worsen over time without treatment.
These results suggest that ERT (possibly in combination
with supportive speech therapy) may be useful to improve
swallowing in PD patients, although this observation in a
single child should be confirmed in larger numbers of
patients and in formal clinical studies.
It is known that PD manifestations have a broad severity
spectrum and respond variably to therapy. The identifica-
tion of reliable measures to follow disease progression and
ERT efficacy has been so far a challenging task. Biochemical
markers of disease severity are unreliable, and administra-
tion of functional tests can be difficult in young patient, or
may be influenced by the operator. VFSS is a safe and non
invasive method to investigate dysphagia, which can be
performed in children by skilled radiologists [23,24]. VFSS
is also useful to get a quantitative severity score of dyspha-
gia with appropriate scales, and to identify airways invasion
or risk for aspiration. If further studies in larger populations
will confirm our data, one could hypothesize that an
accurate evaluation of dysphagia may represent an
additional marker to monitor ERT efficacy.
The pathophysiology of dysphagia in PD patients is not
completely defined. It is possible to speculate that different
mechanisms may concur in causing abnormal swallowing.
These include the dysfunction of bulbar muscles and the
weakness of respiratory muscles and diaphragm that can
lead to impaired coordination of swallowing and breathing.
In addition, recent studies pointed to a possible role of the
involvement of lower motor neurons [20].
In principle, all these mechanisms may coexist in our
patient. However, an effect on the motor neurons can be
excluded, as it is known that ERT cannot cross the blood–
brain-barrier and reach therapeutic levels in the central
nervous system. Therefore, it would be reasonable to think
that the improvement of dysphagia during ERT reflects an
improvement of bulbar muscle and diaphragm function.
Conclusions
In conclusion, we suggest that VFSS and the VFSS-based
score scale are useful tools in the management of PD pa-
tients, to document the presence of dysphagia and to reduce
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only two observations were available, before the start of
ERT and 36 months later. It would be desirable for the
management of PD patients to include serial, periodical
VFSS evaluations, in order to monitor the evolution of dys-
phagia during treatment and to start early appropriate sup-
portive measures. Speech therapy, may be considered, as an
adjunctive therapy, in a multidisciplinary approach for the
treatment of PD patients [25]. Further studies in larger
groups of patients are needed to confirm the possible role
of ERT to improve dysphagia.
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